BioSpace News Archive

Genetown

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

Generation Bio Co. announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the virtual 2024 TD Cowen Genetic Medicines & RNA Summit on Friday, June 21st, 2024 at 1:50 p.m. ET.

June 14, 2024
·
1 min read
Business

TScan Therapeutics Announces Updates to its Board of Directors - June 14, 2024

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, announced changes to its Board of Directors.

June 14, 2024
·
6 min read
Drug Development

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced updated data from multiple combination trials of revumenib, the Company’s potent, selective, small molecule menin inhibitor, in patients with acute leukemias.

June 14, 2024
·
9 min read
Drug Development

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

Cabaletta Bio, Inc. reported positive initial clinical data from each of the first two patients dosed with CABA-201 in the Phase 1/2 RESET-Myositis and RESET-SLE trials.

June 14, 2024
·
13 min read
Genetown

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

Editas Medicine, Inc., a clinical-stage genome editing company, announced new safety and efficacy data in 7 patients with transfusion-dependent beta thalassemia treated with renizgamglogene autogedtemcel in the Phase 1/2 EdiTHAL clinical trial.

June 14, 2024
·
9 min read
Genetown

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress

Vertex Pharmaceuticals Incorporated announced longer-term data for CASGEVY™ from global clinical trials in people with severe sickle cell disease or transfusion-dependent beta thalassemia.

June 14, 2024
·
15 min read
Drug Development

Immune-Onc Therapeutics to Present Additional Positive Interim Data from IO-202 Phase 1b Expansion Cohort in Patients with Chronic Myelomonocytic Leukemia (CMML) at 2024 European Hematology Association (EHA) Annual Congress

Immune-Onc Therapeutics, Inc. announced the company will present additional positive interim Phase 1b expansion cohort data for IO-202 in patients with chronic myelomonocytic leukemia at the 2024 European Hematology Association Annual Meeting held virtually and in Madrid, Spain, June 13 – 16.

June 14, 2024
·
6 min read
Drug Development

Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

Cantargia Cantargia reported progress in the ongoing phase 1 clinical trial of the CAN10 antibody. Seven dose groups have now been concluded without any safety concerns.

June 14, 2024
·
4 min read
Biotech Bay

BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024

BeiGene, Ltd., a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain in an oral session.

June 14, 2024
·
14 min read
BioMidwest

Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials

Enveda Biosciences, a biotechnology company using AI to translate nature into new medicines, announced a new financing round of $55 million to add to its $119 million combined Series B and B1.

June 14, 2024
·
3 min read